Selected Grants
BI1479-0001
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2028Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655
Clinical TrialPrincipal Investigator · Awarded by Nuvalent, Inc. · 2023 - 2027A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Rain Therapeutics, Inc. · 2022 - 2027Methods to improve efficiency and robustness of clinical trials using information from real-world data with hidden bias
ResearchCo Investigator · Awarded by Food and Drug Administration · 2023 - 2026This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 Tumor Proportion Score.
Clinical TrialPrincipal Investigator · Awarded by Mirati Therapeutics, Inc. · 2021 - 2026Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2020 - 2025A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2018 - 2025Empower treatment effects evaluation of randomized clinical trials for elderly patients with integrated real-world data
ResearchCo Investigator · Awarded by North Carolina State University · 2020 - 2025LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living with Metastatic Lung Cancer
ResearchCollaborator · Awarded by National Institutes of Health · 2024 - 2025Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR EXON20 Insertion Mutations
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2023 - 2024Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lu¬¬ng cancer in patients with disease progression after osimertinib"
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2024Dialectical Behavioral Therapy Skills Training for Metastatic Lung Cancer Patients
FellowshipMentor · Awarded by National Institutes of Health · 2021 - 2024A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Advaxis Inc · 2019 - 2023A Single Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations Thoracic Oncology Program (TOP) Protocol Number: TOP 1703
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca LP · 2018 - 2023Phase 2 Trial of Brigatinib after Treatment with Second-Generation ALK inhibitors in Refractory ALK Rearranged NSCLC
Clinical TrialPrincipal Investigator · Awarded by Millennium Pharmaceuticals, Inc. · 2017 - 2022A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Merck · 2017 - 2022Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2016 - 2021Mechanisms of immune checkpoint resistance mediated by LKB1 tumor suppressor in lung cancer
ResearchCo-Mentor · Awarded by Department of Defense · 2019 - 2021A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2020 - 2020A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by TESARO · 2018 - 2020A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2017 - 2020A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of embrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squam
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2019 - 2020Safety, Activity, and Pharmacology of Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2019 - 2020A Phase 1b/2, single-arm, open-label, multi-center study of MP0250 in combination with osimertinib in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) pretreated with osimertinib
Clinical TrialPrincipal Investigator · Awarded by Molecular Partners AG · 2018 - 2020A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2017 - 2018A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2017 - 2018External Relationships
- AstraZeneca
- Blueprint Medicines
- Boehringer Ingelheim
- Coherus Bioscience
- G1 Therapeutics, Inc.
- GSK
- Gilead Sciences, Inc.
- Pfizer
- Roche/Genentech
- Spectrum Pharmaceuticals
- Takeda Oncology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.